Market Overview

Gilead's HepC Drug Sales May Be More Resilient Than Feared


Investors are fearful the launch of Gilead's (NASDAQ: GILD) HepC franchise has been too “rapid,” which will cause the drug's market share to plateau and decline. There are also concerns of reimbursement headwinds in state Medicaid programs “as CO, PA, and Utah have decided against reimbursing for Sovaldi at the point,” Citigroup analyst Yaron Werber said.

Werber is not as concerned as “the launch is staggered globally,” which should provide “more resilience than feared.”

The analyst estimated HepC sales will total $7.5, $11, and $12 billion in 2014, ‘15 and ‘16, respectively, and expects sales to fall to $6.5 billion by 2023.

Werber has a Buy rating on the stock and $96 price target.

Shares of Gilead are up 0.86 percent to $74.29 in Wednesday's trading.

Latest Ratings for GILD

Nov 2019Initiates Coverage OnHold
Oct 2019MaintainsOutperform
Oct 2019DowngradesBuyHold

View More Analyst Ratings for GILD
View the Latest Analyst Ratings

Posted-In: Citigroup Yaron WerberAnalyst Color Analyst Ratings


Related Articles (GILD)

View Comments and Join the Discussion!

Latest Ratings

TDCanaccord GenuityMaintains79.0
CWBCanaccord GenuityMaintains34.0
CMCanaccord GenuityMaintains108.0
CRWDBank of AmericaMaintains86.0
CLDRBank of AmericaMaintains8.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Trading Daily
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at

3 Retailers Ready For Spring And Summer

Utilities Stocks Lead Market Higher, Signal Defensive Shift